202 related articles for article (PubMed ID: 24893961)
1. A hyaluronic acid-methotrexate conjugate for targeted therapy of rheumatoid arthritis.
Shin JM; Kim SH; Thambi T; You DG; Jeon J; Lee JO; Chung BY; Jo DG; Park JH
Chem Commun (Camb); 2014 Jul; 50(57):7632-5. PubMed ID: 24893961
[TBL] [Abstract][Full Text] [Related]
2. Methotrexate: a gold standard for treatment of rheumatoid arthritis.
Shinde CG; Venkatesh MP; Kumar TM; Shivakumar HG
J Pain Palliat Care Pharmacother; 2014 Dec; 28(4):351-8. PubMed ID: 25322199
[TBL] [Abstract][Full Text] [Related]
3. Novel hyaluronic acid-methotrexate conjugate suppresses joint inflammation in the rat knee: efficacy and safety evaluation in two rat arthritis models.
Tamura T; Higuchi Y; Kitamura H; Murao N; Saitoh R; Morikawa T; Sato H
Arthritis Res Ther; 2016 Apr; 18():79. PubMed ID: 27039182
[TBL] [Abstract][Full Text] [Related]
4. Endogenous inspired biomineral-installed hyaluronan nanoparticles as pH-responsive carrier of methotrexate for rheumatoid arthritis.
Alam MM; Han HS; Sung S; Kang JH; Sa KH; Al Faruque H; Hong J; Nam EJ; Kim IS; Park JH; Kang YM
J Control Release; 2017 Apr; 252():62-72. PubMed ID: 28288894
[TBL] [Abstract][Full Text] [Related]
5. Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis.
Wunder A; Müller-Ladner U; Stelzer EH; Funk J; Neumann E; Stehle G; Pap T; Sinn H; Gay S; Fiehn C
J Immunol; 2003 May; 170(9):4793-801. PubMed ID: 12707361
[TBL] [Abstract][Full Text] [Related]
6. Methotrexate in the Treatment of Psoriasis and Rheumatoid Arthritis: Mechanistic Insights, Current Issues and Novel Delivery Approaches.
Rajitha P; Biswas R; Sabitha M; Jayakumar R
Curr Pharm Des; 2017; 23(24):3550-3566. PubMed ID: 28571554
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of concurrent administration of cilostazol and methotrexate in rheumatoid arthritis: pharmacologic and clinical significance.
Kim HY; Lee SW; Park SY; Baek SH; Lee CW; Hong KW; Kim CD
Life Sci; 2012 Sep; 91(7-8):250-7. PubMed ID: 22820172
[TBL] [Abstract][Full Text] [Related]
8. New autoinjector technology for the delivery of subcutaneous methotrexate in the treatment of rheumatoid arthritis.
Schiff M; Jaffe J; Freundlich B; Madsen P
Expert Rev Med Devices; 2014 Sep; 11(5):447-55. PubMed ID: 24934630
[TBL] [Abstract][Full Text] [Related]
9. Methotrexate transport mechanisms: the basis for targeted drug delivery and ß-folate-receptor-specific treatment.
Fiehn C
Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S40-5. PubMed ID: 21044432
[TBL] [Abstract][Full Text] [Related]
10. Novel hyaluronic acid-methotrexate conjugates for osteoarthritis treatment.
Homma A; Sato H; Okamachi A; Emura T; Ishizawa T; Kato T; Matsuura T; Sato S; Tamura T; Higuchi Y; Watanabe T; Kitamura H; Asanuma K; Yamazaki T; Ikemi M; Kitagawa H; Morikawa T; Ikeya H; Maeda K; Takahashi K; Nohmi K; Izutani N; Kanda M; Suzuki R
Bioorg Med Chem; 2009 Jul; 17(13):4647-56. PubMed ID: 19457673
[TBL] [Abstract][Full Text] [Related]
11. Targeted delivery of hyaluronic acid-coated solid lipid nanoparticles for rheumatoid arthritis therapy.
Zhou M; Hou J; Zhong Z; Hao N; Lin Y; Li C
Drug Deliv; 2018 Nov; 25(1):716-722. PubMed ID: 29516758
[TBL] [Abstract][Full Text] [Related]
12. Parenteral methotrexate for the treatment of rheumatoid arthritis.
Yazici Y; Bata Y
Bull Hosp Jt Dis (2013); 2013; 71 Suppl 1():46-8. PubMed ID: 24219041
[TBL] [Abstract][Full Text] [Related]
13. Reduced folate carrier-1 80G>A polymorphism affects methotrexate treatment outcome in rheumatoid arthritis.
Drozdzik M; Rudas T; Pawlik A; Gornik W; Kurzawski M; Herczynska M
Pharmacogenomics J; 2007 Dec; 7(6):404-7. PubMed ID: 17325736
[TBL] [Abstract][Full Text] [Related]
14. Hyaluronate-functionalized hydroxyapatite nanoparticles laden with methotrexate and teriflunomide for the treatment of rheumatoid arthritis.
Pandey S; Rai N; Mahtab A; Mittal D; Ahmad FJ; Sandal N; Neupane YR; Verma AK; Talegaonkar S
Int J Biol Macromol; 2021 Feb; 171():502-513. PubMed ID: 33422513
[TBL] [Abstract][Full Text] [Related]
15. Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving long-term methotrexate therapy.
Stamp LK; O'Donnell JL; Chapman PT; Zhang M; James J; Frampton C; Barclay ML
Arthritis Rheum; 2010 Feb; 62(2):359-68. PubMed ID: 20112376
[TBL] [Abstract][Full Text] [Related]
16. [Comparison of efficacy and tolerability of triple combination therapy (methotrexate + sulfasalazine + hydroxychloroquine) with methotrexate monotherapy in patients with rheumatoid arthritis].
Gubar' EE; Bochkova AG; Bunchuk NV
Ter Arkh; 2008; 80(5):25-30. PubMed ID: 18590110
[TBL] [Abstract][Full Text] [Related]
17. Hyaluronic acid-coated solid lipid nanoparticles enhance antirheumatic activity and reduce toxicity of methotrexate.
Mirchandani Y; Patravale VB; Brijesh S
Nanomedicine (Lond); 2022 Jul; 17(16):1099-1114. PubMed ID: 36178114
[TBL] [Abstract][Full Text] [Related]
18. Targeted chemo-photothermal treatments of rheumatoid arthritis using gold half-shell multifunctional nanoparticles.
Lee SM; Kim HJ; Ha YJ; Park YN; Lee SK; Park YB; Yoo KH
ACS Nano; 2013 Jan; 7(1):50-7. PubMed ID: 23194301
[TBL] [Abstract][Full Text] [Related]
19. [Methotrexate for the treatment of rheumatoid arthritis in Japan--much more still remains to be resolved].
Suzuki Y
Nihon Rinsho; 2002 Dec; 60(12):2331-8. PubMed ID: 12510358
[TBL] [Abstract][Full Text] [Related]
20. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.
Breedveld FC; Weisman MH; Kavanaugh AF; Cohen SB; Pavelka K; van Vollenhoven R; Sharp J; Perez JL; Spencer-Green GT
Arthritis Rheum; 2006 Jan; 54(1):26-37. PubMed ID: 16385520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
